Survival rates were similar between the 2 drugs, but acalabrutinib had fewer adverse events.
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners
Latest from The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James)
An expert discusses how clinicians choose between PARP inhibitors for patients with ovarian cancer, and what may be coming next in the field.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Race Identified as Prognostic Indicator in Black Patients With AML
2
FDA Approves Liso-Cel in Pretreated R/R Marginal Zone Lymphoma
3
Families of Children With ALL Face Extreme Financial Toxicity
4
Odronextamab/CHOP Yields Early Efficacy in Untreated DLBCL
5
